FDA Is Not Your CMC Strategy

That is not strategy. That is hesitation dressed up as regulatory engagement.

FDA meetings matter. Agency feedback matters. But the FDA is not there to design your development plan for you. It is not there to connect your manufacturing story, define your control philosophy, explain your comparability logic, or rescue a program that has never made its own hard decisions.

Yet that is exactly how many teams behave. They treat feedback like a roadmap, minutes like a blueprint, and reviewer comments like a substitute for internal strategic thinking.

That is where the trouble starts.

A strong CMC strategy is supposed to exist before the meeting. It should already reflect the product’s stage of development, its technical realities, the risks that matter most, the gaps that can be defended, and the story that will eventually need to hold together in the dossier. The meeting is where you pressure-test that strategy. It is not where you invent one.

Too often, emerging teams arrive with fragmented data, loose assumptions, and a vague hope that the agency will “give direction.” But FDA feedback is rarely a complete answer. It is usually narrow, conditional, and tied to the way the question was framed.

If your question is weak, overly open-ended, or disconnected from a clear position, the answer will be just as limited. And if your team has no real CMC point of view going in, what comes back is often misread as broader endorsement than it really is.

That creates a dangerous illusion.

The company leaves feeling reassured. The internal team says the agency is “aligned.” The development path continues. And months later, when the data mature, the process shifts, the analytical package tightens, or the Module 3 story starts coming together, it becomes obvious there was never a real strategy underneath it all. There was only a collection of comments, meeting notes, and assumptions stitched together into false confidence.

CMC strategy does not come from waiting for regulators to speak first. It comes from knowing what matters before they do.

That means deciding early what your development story is. What are you trying to justify? What is phase-appropriate and what is simply underdeveloped? Where are the actual risks in formulation, process, analytical control, stability, sourcing, comparability, and scale-up?

Which decisions are temporary and defendable, and which ones are quietly setting you up for future pain? What will this look like when it has to be explained clearly in Module 3 and supported in the Quality Overall Summary?

Those are strategic questions. They are not agency handoffs.

The best FDA interactions happen when a company walks in with a real position. Not arrogance. Not rigidity. A position. One grounded in data, shaped by experience, and framed in a way that gives the agency something useful to react to. That is how good questions get asked.

That is how useful feedback gets generated. That is how meetings become high-value moments instead of expensive exercises in uncertainty.

The uncomfortable truth is that many companies do not want strategy. They want permission. Permission to delay hard choices. Permission to move forward without fully resolving the story. Permission to treat regulatory interaction like outsourced judgment.

But FDA does not own your product. You do.

And if your CMC plan only becomes visible after the agency responds, it was never really a strategy to begin with.

The companies that move best are not the ones that ask FDA what to do at every turn. They are the ones that build a coherent, phase-appropriate, risk-based plan early, then use agency feedback to refine it—not create it from scratch.

That is the difference between leading development and reacting to it.

FDA feedback can strengthen a strategy.

It cannot replace one.

Enkrisi, which means Approval in Greek, was founded on the premise that biotechnology, medical devices, and pharmaceuticals hold the promise of a better future for everyone. Making good on that promise requires innovative approaches, world-class science, regulatory know-how, and a team dedicated to bringing all of it together.

We’re more than a team of experts, we’re your partners!

Contact us Here. enarke@enkrisi.com